Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Published

Journal Article

There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease. However, because it is associated with hyperinsulinemia and insulin-resistance, insulin-sensitizing agents might be beneficial. To evaluate this possibility, insulin-resistant ob/ob mice with fatty livers were treated with metformin, an agent that improves hepatic insulin-resistance. Metformin improved fatty liver disease, reversing hepatomegaly, steatosis and aminotransferase abnormalities. The therapeutic mechanism likely involves inhibited hepatic expression of tumor necrosis factor (TNF) alpha and TNF-inducible factors that promote hepatic lipid accumulation and ATP depletion. These findings suggest a mechanism of action for metformin and identify novel therapeutic targets in insulin-resistant states.

Full Text

Duke Authors

Cited Authors

  • Lin, HZ; Yang, SQ; Chuckaree, C; Kuhajda, F; Ronnet, G; Diehl, AM

Published Date

  • September 2000

Published In

Volume / Issue

  • 6 / 9

Start / End Page

  • 998 - 1003

PubMed ID

  • 10973319

Pubmed Central ID

  • 10973319

Electronic International Standard Serial Number (EISSN)

  • 1546-170X

International Standard Serial Number (ISSN)

  • 1078-8956

Digital Object Identifier (DOI)

  • 10.1038/79697

Language

  • eng